metformin + fenofibrate placebo

Metformin + fenofibrate placebo refers to the pharmacologically inactive control intervention utilized in the Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study (NCT00650754). This phase 2 clinical trial, sponsored by the University of Pennsylvania, was designed to evaluate the individual and combined therapeutic effects of metformin (an insulin sensitizer) and fenofibrate (a PPAR-alpha agonist) in adults presenting with metabolic syndrome, insulin resistance, and atherogenic dyslipidemia (specifically elevated triglycerides). The placebo arm was administered matching non-active formulations that mimicked the appearance and dosing schedule of the active treatments (2000 mg/day of metformin and 145 mg/day of fenofibrate) to maintain the double-blind nature of the study. As a placebo, it contains no active pharmaceutical ingredients and serves as a comparative baseline to differentiate the pharmacological effects of the active drugs from the placebo effect and natural disease progression.

Other names

Metformin and Fenofibrate placebometformin + fenofibrate placebo-University of Pennsylvania-metabolic syndrome-atherogenic dyslipidemia-insulin resistance